At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SMMT Summit Therapeutics PLC
Post-Market Trading 06-21 16:13:43 EDT
7.93
+0.13
+1.67%
盘后7.78
-0.15-1.89%
16:12 EDT
High8.15
Low7.71
Vol8.15M
Open7.79
D1 Closing7.80
Amplitude5.64%
Mkt Cap5.57B
Tradable Cap581.53M
Total Shares701.98M
T/O64.60M
T/O Rate11.11%
Tradable Shares73.33M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Summit Therapeutics Announces Board Changes and Shareholder Approvals
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.